ALFA FinderBSE filing, NSE: SENORES. Summary written from the filing by ALFA Finder's alert engine.
Senores Pharmaceuticals Ltd: key numbers
- Share price
- ₹1,175.00
- Market cap
- ₹5,411 Cr
- Revenue (annual)
- ₹632.6 Cr
- Net profit (annual)
- ₹115.4 Cr
- P/E (TTM)
- 40.5×Sector 43.4×
- Promoter holding
- 45.82%+0.00% QoQ
- FII holding
- 6.01%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Senores Pharmaceuticals Ltd
All →Senores Pharmaceuticals Earnings Call Transcript: Key Takeaways
Senores delivered record quarterly revenue and EBITDA, driven by US portfolio expansion and regulated market growth.
- Call
- Guides 40% growth
Senores Pharmaceuticals Other Announcement
Senores Pharmaceuticals reported no deviation in utilising the Rs 95 Crore raised via a preferential warrant issue for the quarter ended September 30, 2026. Audit Committee reviewed the statement and the Board took it on record.
- Value
- ₹95.00 Cr
Senores Pharmaceuticals Capacity Expansion: ₹20 Cr Investment
Senores Pharmaceuticals' subsidiary Apnar Pharma Private Limited plans a 0.7 Bn unit capacity addition by March 2027. The investment is Rs.20.00 Crore, funded by internal accruals and IPO proceeds.
- Value
- ₹20.00 Cr
- Execution
- By end of March 2027
- production capacity
- 0.7 Bn units
Senores Pharmaceuticals Capacity Expansion: ₹18 Cr Investment
Senores Pharmaceuticals plans to add 0.8 Bn units of capacity to its existing 1.2 Bn unit plant by March 2027. The investment is Rs.18.00 Crore, funded by internal accruals and IPO proceeds.
- Value
- ₹18.00 Cr
- Execution
- By end of March 2027
- production capacity
- 0.8 Bn units
Senores Pharmaceuticals Other Announcement
Senores Pharmaceuticals appointed Talati and Talati LLP as Statutory Auditor for a 60-month term, effective 29 October 2026. The appointment was approved at the board meeting held the same day.
- Execution
- 60 months
Senores Pharmaceuticals Investor Presentation: Key Takeaways
Q2 FY27 revenue ₹192.3 Cr (+24.9%), EBITDA ₹57.7 Cr (+38.3%, 30.0% margin), PAT ₹36.6 Cr. H1 revenue +30%, EBITDA +58.2%.
Other business update announcements
All →JSW Steel Business Update
JSW Steel reported consolidated crude steel production of 25.73 lakh tonnes for October 2026, up 19% YoY. Indian operations ran at 92% capacity utilisation.
HEG Advanced Materials Business Update
HEG subsidiary TACC received a Rs 609.50 Crore ECMS incentive approval for its Dewas anode plant. Phase one targets 20,000 MTPA output from June 2027.
- Value
- ₹609.5 Cr
- anode material capacity
- 20000.0 MTPA
Jubilant Pharmova Business Update
Jubilant Pharmova's subsidiary Jubilant Therapeutics will present preliminary Phase 1 clinical data for JBI-802 at the 68th ASH meeting. A company event on December 14, 2026 will discuss the data.
Globus Spirits Business Update
Globus Spirits received Canteen Stores Department approval to stock its DOAAB Single Malt Whisky. This opens access to all CSD outlets nationwide, expanding distribution reach.
Jindal Stainless Business Update
Jindal Stainless won 95 Gold and 6 Silver awards at QCFI quality conventions in 2026 for employee-led quality initiatives. The awards carry no financial value and do not affect orders or capacity.
IRB Infrastructure Developers Business Update
IRB Infrastructure reported October 2026 gross toll revenue of ₹836 Crore, up about 26% year-on-year, across its 24 SPVs. The filing is a monthly operating update with no new contract, financing or capital event.